Tenofovir Disoproxil FumarateThird Party Manufacturing in India

Tenofovir Disoproxil Fumarate works as an acyclic nucleoside phosphonate diester prodrug that requires initial ester hydrolysis for conversion to tenofovir, followed by cellular phosphorylation to tenofovir diphosphate. It binds competitively to viral reverse transcriptase to help the body incorporate the fraudulent nucleotide into viral DNA, resulting in immediate chain termination due to the absence of a 3' hydroxyl group. Unlike traditional nucleoside analogues, its structural stability provides a prolonged intracellular half-life. It is highly effective and well-tolerated for suppressing chronic viral replication.

Therapeutic Uses

• HIV-1 Infection: Formulated as a core component of antiretroviral regimens to treat adults and pediatric patients.
• Chronic Hepatitis B Management: Suppresses HBV DNA replication effectively, helping reduce hepatic inflammation and associated fibrosis.
• Pre-Exposure Prophylaxis (PrEP): Utilized in high-risk populations to prevent sexual acquisition of HIV-1 infection.

Why Manufacturers Choose Tenofovir Disoproxil Fumarate

Partnering for Tenofovir Disoproxil Fumarate third party manufacturing in India is essential for companies aiming to participate in institutional government supply models and global health programs. The compound is sensitive to heat and moisture, which necessitates specialized environmental control during the granulation phase. Our partner facilities offer high-output, climate-stabilized production suites that satisfy all WHO-GMP parameters, ensuring excellent stability and optimal bioavailability profiles.